NDA 021991 · Msd Sub Merck
Zolinza
Vorinostat · Oral · Histone Deacetylase Inhibitor
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Dec 11, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2006
Oct 6, 2006
Approved uses
2
Original approval plus efficacy supplements
Registered trials
278
9 Phase 3, 10 recruiting
FAERS reports
2,165
1,872 serious, 423 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 12, 2024.
ZOLINZA ® is indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies. ZOLINZA is a histone deacetylase (HDAC) inhibitor indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies. ( 1 )
Mechanism: Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC 50 <86 nM). These enzymes catalyze the removal of acetyl groups from the lysine residues of proteins, including histones and transcription factors. In some cancer cells, there is an overexpression of HDACs, or an aberrant recruitment of HDACs to oncogenic transcription factors causing hypoacetylation of core nucleosomal histones. Hypoacetylation of histones is associated with a condensed chromatin structure and repression of gene...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 23, 2009 Supplement 4 · Efficacy LetterLabel
- Oct 6, 2006 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLetterLabelReview
1 products under this application
- ZOLINZA · VORINOSTAT 100MG · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Vorinostat" as an intervention, any sponsor and status, largest first.
- Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma PatientsPivotal-lookingStatus unknown
University of LeedsAcademic, hospital or other
NCT01554852 · 4,420 participants · Start May 2010 · Primary completion Dec 2021
Drug: Induction (intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone (CRD) regimen; Induction (intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone (CTD) regimen and 7 more · For: Multiple Myeloma
Sites: United Kingdom, United Kingdom
- Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and LymphomaPivotal-lookingActive, not recruiting
St. Jude Children's Research HospitalAcademic, hospital or other
NCT03117751 · 790 participants · Start Mar 29, 2017 · Primary completion Sep 30, 2026
Drug: Prednisone; Vincristine and 21 more · For: Acute Lymphoblastic Leukemia; Acute Lymphoblastic Lymphoma
Sites: Palo Alto, California; San Diego, California; Peoria, Illinois · 8 sites in all
- Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid LeukemiaPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT01802333 · 754 participants · Start Feb 12, 2013 · Primary completion Jun 15, 2017
Drug: Cytarabine; Daunorubicin Hydrochloride and 2 more · For: Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia
Sites: Birmingham, Alabama; Anchorage, Alaska; Tucson, Arizona · 447 sites in all
- Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00128102 · 661 participants · Start Jun 30, 2005 · Primary completion Jul 15, 2011
Drug: Vorinostat; Placebo · For: Mesothelioma; Lung Cancer
- Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00773747 · 637 participants · Start Dec 1, 2008 · Primary completion Sep 8, 2011
Drug: Vorinostat; bortezomib and 1 more · For: Multiple Myeloma
- Pediatric Precision Laboratory Advanced Neuroblastoma TherapyPivotal-lookingRecruiting
Giselle ShollerAcademic, hospital or other
NCT02559778 · 500 participants (planned) · Start Sep 2015 · Primary completion Sep 2030
Drug: Ceritinib; dasatinib and 3 more · For: Neuroblastoma
Sites: Birmingham, Alabama; Little Rock, Arkansas; Oakland, California · 28 sites in all
- Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCLPivotal-lookingCompleted
Kyowa Kirin, Inc.Industry
NCT01728805 · 372 participants · Start Nov 2012 · Primary completion Mar 2017
Drug: KW-0761; Vorinostat · For: Cutaneous T-Cell Lymphoma
Sites: Birmingham, Alabama; Gilbert, Arizona; Duarte, California · 73 sites in all
- Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic LeukemiaPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT01522976 · 282 participants · Start Mar 1, 2012 · Primary completion Jun 1, 2015
Drug: Azacitidine; Lenalidomide and 1 more · For: Chronic Myelomonocytic Leukemia; Chronic Myelomonocytic Leukemia-1; Chronic Myelomonocytic Leukemia-2 and 4 more
Sites: Birmingham, Alabama; Mobile, Alabama; Scottsdale, Arizona · 294 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- febrile neutropenia239
- thrombocytopenia153
- anaemia135
- product use in unapproved indication133
- diarrhoea130
- nausea128
- fatigue126
- off label use115
- vomiting113
- sepsis111
- platelet count decreased106
- dehydration102
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2006 | 3 |
| 2007 | 43 |
| 2008 | 52 |
| 2009 | 54 |
| 2010 | 82 |
| 2011 | 56 |
| 2012 | 190 |
| 2013 | 263 |
| 2014 | 284 |
| 2015 | 291 |
| 2016 | 106 |
| 2017 | 91 |
| 2018 | 96 |
| 2019 | 46 |
| 2020 | 110 |
| 2021 | 88 |
| 2022 | 141 |
| 2023 | 54 |
| 2024 | 50 |
| 2025 | 36 |
| 2026 | 29 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Zolinza (Vorinostat)
2024 spending
$3.7M
Beneficiaries
75
387 claims
Per beneficiary
$49,294
$119.78 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $3,137,397 |
| 2021 | $3,249,001 |
| 2022 | $3,907,317 |
| 2023 | $3,402,208 |
| 2024 | $3,697,070 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
Kim YH, Bagot M, Pinter-Brown L, et al. · Lancet Oncol 2018 · Clinical Trial, Phase III, Comparative Study
- Interventions for mycosis fungoides.
Valipour A, Jäger M, Wu P, et al. · Cochrane Database Syst Rev 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Epigenetic profiling identifies markers of endocrine resistance and therapeutic options for metastatic castration-resistant prostate cancer.
Severson TM, Minnee E, Zhu Y, et al. · Cell Rep Med 2025 · Clinical Trial, Phase II
- Broad activation of latent HIV-1 in vivo.
Barton K, Hiener B, Winckelmann A, et al. · Nat Commun 2016 · Clinical Trial, Research Support, N.I.H., Extramural
- Maintenance therapy in multiple myeloma: Two is not always better than one.
Offidani M, Morè S, Corvatta L · Br J Haematol 2023 · Randomized Controlled Trial, Multicenter Study
- Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer.
Terranova-Barberio M, Pawlowska N, Dhawan M, et al. · Nat Commun 2020 · Clinical Trial, Phase II, Randomized Controlled Trial
Sponsor: Merck & Co.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.